8-K: Current report filing
Published on May 8, 2001
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
______________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) May 8, 2001
-----------
COMMONWEALTH BIOTECHNOLOGIES, INC.
----------------------------------
(Exact Name of Registrant as Specified in Charter)
Virginia 001-13467 56-1641133
- ----------------- --------- ----------
(State or Other (Commission File Number) (IRS Employer
Jurisdiction of Identification No.)
Incorporation)
601 Biotech Drive, Richmond, Virginia 23235
---------------------------------------- -----
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (804) 648-3820
---------------
N/A
------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Item 5. Other Events.
On May 8, 2001, Commonwealth Biotechnologies, Inc. (the "Registrant") issued a
press release relating to the settlement of the Registrant's patent dispute with
Applied Biosystems. A copy of the press release relating to the announcement is
attached as an exhibit hereto.
Item 7. Financial Statements and Exhibits.
(a) Financial Statements of Businesses Acquired.
Not applicable.
(b) Pro Forma Financial Information.
Not applicable.
(c) Exhibits.
99.1 Press Release, dated May 8, 2001, relating to the settlement
of the Registrant's patent dispute with Applied Biosystems.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
COMMONWEALTH BIOTECHNOLOGIES, INC.
By: /s/ Richard J. Freer, Ph.D.
----------------------------------------
Richard J. Freer, Ph.D.
Chairman
May 8, 2001
3
EXHIBIT INDEX
Number Description of Exhibit
- ------ ----------------------
99.1 Press Release, dated May 8, 2001, relating to the settlement of
the Registrant's patent dispute with Applied Biosystems.
4